It has been demonstrated that aortic stiffness is an independent predictor of cardiovascular disease. We investigated whether this measure is of use in cardiovascular risk stratification in clinical practice for elderly subjects (mean age 71.5 years). Within the framework of the Rotterdam Study, we stratified subjects free of coronary heart disease (CHD) at baseline into categories of low (o10%), intermediate (10-20%) and high (420%) 10-year risk of CHD based on Framingham risk factors. Within each risk category, we determined the percentages of subjects moving into a higher or lower risk category when adding aortic stiffness to the Framingham risk factors. Among 2849 participants, 223 CHD events occurred during a median follow-up of 7.9 years.
Introduction
Primary prevention of coronary heart disease (CHD) is based on the assessment of traditional cardiovascular risk factors, including older age, male gender, hypercholesterolaemia, low levels of high-density lipoprotein cholesterol, smoking, hypertension and diabetes mellitus. Treatment of these risk factors has shown to reduce cardiovascular morbidity and mortality. Current guidelines recommend algorithms such as SCORE, 1 
risk chart or Framingham
Risk Score 2 for predicting the 10-year absolute risk for CHD. Noninvasive measures of arterial stiffness, as the aortic pulse wave velocity (aPWV), have shown to be independent risk factors of CHD 3, 4 and, therefore, are proposed as addition to traditional risk factor for predicting incident CHD. 5 The recent European guidelines for the diagnosis and treatment of hypertension suggest that an aPWV higher than 12 m s À1 is a marker of target-organ damage. 6 However, whether measures of arterial stiffness are of use in cardiovascular risk prediction in clinical practice needs to be determined.
We have investigated the predictive value of aPWV beyond traditional risk factor assessment in an ongoing population-based prospective study in the elderly. Subjects were stratified in three risk categories, namely low (o10%), intermediate (10-20%) and high (420%), based on the Framingham risk factors. We determined the percentages of subjects moving into a higher or lower risk category when adding aPWV to the Framingham risk factors.
Methods

Study population
This study is performed within the framework of the Rotterdam Study, a population-based prospective cohort study in Ommoord, a suburb of Rotterdam, The Netherlands. Overall aim of the Rotterdam Study is assessing the occurrence of and risk factors for chronic diseases. The study design and objectives of the Rotterdam Study are described elsewhere. 7 Briefly, the baseline visit started between 1990 and 1993. All inhabitants of Ommoord, aged 55 years and older were invited to participate (n ¼ 10 275). Of them, 7983 (78%) gave their written informed consent and took part in the baseline examination. Since the start of the study, follow-up visits took place in the period 1993 through 1996 for the second visit, in the period 1997 through 1999 for the third visit, and in the period 2002 through 2004 for the fourth visit. A flow diagram of the Rotterdam Study is provided in Figure 1 . During the third examination phase, which took place from 1997 until 1999, a computerised questionnaire was completed and assessment of cardiovascular risk factors and arterial stiffness were performed. A total of 4024 participants visited the research center, of these, 3445 persons had an aPWV measurement.
Missing information on aPWV was primarily because of logistic reasons, including illness of the cardiovascular research assistants, maintenance service of the Complior device and temporary technical problems with the Complior device, and is therefore likely to be randomly distributed. Prevalent CHD was defined as a history of clinically manifest myocardial infarction, coronary artery bypass grafting or percutaneous transluminal coronary angioplasty. We excluded subjects with prevalent CHD and stroke at the third examination (n ¼ 581), and subjects lost to follow-up (n ¼ 15). The current analysis was carried out in 2849 subjects. The Medical Ethics Committee of Erasmus Medical Center approved the study and written consent was obtained from all participants.
Aortic stiffness
Carotid-femoral pulse wave velocity, a measure of aortic stiffness, was obtained with subjects in supine position. Before the aPWV measurement, blood pressure was measured twice in supine position with a sphygmomanometer after five minutes of rest and the mean value was taken. Measurements of aPWV were performed during the morning or afternoon (no specific time) and the subjects were nonfasting. The aPWV was assessed with an automatic device (Complior Artech Medical, Pantin, France) 8 that measures the time delay between the rapid upstroke of the feet of simultaneously recorded pulse waves in the carotid artery and the femoral artery. The distance between the recording sites in the carotid and 1990 -1993 1993 -1995 1997 -1999 
-2004
Rotterdam Study
7983 subjects participating in the first research round 6315 subjects participating in the second research round 504 participants died 11 were lost to follow-up or were not invited 1153 did not participate in the second research round 4797 subjects participating in the third research round 3550 subjects participating in the fourth research round 1049 participants died 6 were lost to follow-up or were not invited 463 did not participate in the third research round 765 participants died 35 were lost to follow-up or were not invited 447 did not participate in the fourth research round the femoral artery was measured with a tape over the surface of the body. The aPWV was calculated as the ratio between distance and the foot-to-foot time delay, and was expressed in metres per second.
Cardiovascular risk factors
Information on medical history, smoking habits and the use of antihypertensive medication was obtained during the interview. Two seated blood pressure measurements were obtained at the right brachial artery with a random zero sphygmomanometer. Diabetes mellitus was defined as a history of diabetes mellitus and/or the use of blood glucose lowering medication and/or a fasting serum glucose level equal to or higher than 7.0 mmol l À1 . 9 Serum total cholesterol and high-density lipoproteins cholesterol values were determined by an automated enzymatic procedure (Boehringer Mannheim System, Mannheim, Germany). 10 
Clinical outcomes
The follow-up procedure has previously been described in detail. 11 Briefly, information on fatal and nonfatal coronary endpoints was obtained through automated linkage with files from general practitioners and letters, and discharge reports from medical specialists. Two research physicians independently coded all reported events according to the International Classification of disease, 10th edition. 12 In case of disagreement, consensus was reached. A medical expert in cardiovascular disease, whose judgment was considered final, reviewed all events. CHD was defined as the occurrence of fatal or nonfatal myocardial infarction (ICD-10 code I21), percutaneous transluminal coronary angioplasty, coronary artery bypass grafting and CHD mortality. In identifying myocardial infarctions, all available information, which included ECG, cardiac enzyme levels and the clinical judgment of the treating specialist, was used. If a nonfatal event occurred within 28 days before CHD death, the event was contributed to CHD mortality.
Statistical analysis
Mean values with s.d. and percentages were calculated for continuous and categorical baseline variables, respectively. The baseline characteristics of males and females were compared using Student's t-test for continuous variables and w 2 -test for categorical variables.
aPWV and risk of CHD Cox proportional hazard analysis was performed to estimate the hazard ratios with corresponding 95% confidence interval for CHD associated with tertiles of aPWV. Analyses were adjusted for age and gender, and additionally for current smoking, total cholesterol, high-density lipoproteins cholesterol, systolic blood pressure, use of antihypertensive medication and diabetes mellitus.
Prediction model
We used a Weibull survival model to predict individual 10-year CHD risk probabilities and to classify persons into a priori defined risk categories. 2 These categories were low (o10%), intermediate (10-20%) and high (420%) 10-year risk of total CHD events. We restricted the predictors of the model to components of the Framingham Risk Score, in accordance with the ATP III guidelines. 2 The model included age, gender, systolic blood pressure, use of antihypertensive medication, total cholesterol, high-density lipoproteins cholesterol, diabetes mellitus and current smoking (yes/no). Additionally, we extended the first model with aPWV (model 2). To allow for possible nonlinear effects, we used restricted cubic splines with three knots for continuous variables. We examined global model fit using Nagelkerke's generalised model R 2 . This is a measure of the fraction of À2-log likelihood explained by the predictors, analogous to the percentage of variance explained in a linear model. Higher percentages indicate better model fit. 13, 14 Furthermore, as a measure of discrimination we used the c-index that is defined as the proportion of all pairs of patients whose survival time can ordered such that the patient who survived longer has the higher predicted survival. [15] [16] [17] For internal validation of the model, we used bootstrap sampling (150 samples) to correct for overoptimism and calculated the bootstrap adjusted Nagelkerke's R 2 . To determine how well the model predicts disease, the calibration of the model was evaluated by comparing the predicted 10-year risk probabilities with observed 10-year risk in the three risk categories (low, intermediate, high-risk). We computed reclassification percentages to study the incremental ability of aPWV to classify subjects in risk categories according to the commonly used categories of 10-year CHD risk (low, intermediate, high-risk).We used the reclassification approach comparable with the method previously used by Cook et al. 18 To evaluate true improvement in classification by addition of PWV to the 'Framingham model', we calculated the net reclassification improvement by the method of Steyerberg and Pencina, which is specially designed for survival data. 19 In case of missing values for the Framingham predictors, values were imputed using the Expectation Maximisation method. Analyses were performed using SPSS version 15 (SPSS, INC., Chicago, IL, USA) and R version 2.7.2 software (R Foundation for Statistical Computing, Vienna, Austria).
Results
The baseline characteristics of the 2849 participants are shown in Table 1 . The population of this study consisted of 1097 men (38.5%) and 1752 women. Mean age at baseline was 70.9 years for men and 71.9 years for women (Po0.001). More men than women were smokers (17.8 vs 14.2%, Po0.001) and women used more frequently antihypertensive medication (25.3 vs 19.9%, P ¼ 0.001) and serum lipid reducing agents (11.0 vs 7.4%, P ¼ 0.002). The mean aPWV in men was slightly higher than in women (13.7 vs 13.1 m s À1 ; Po0.001). The median follow-up duration (inter-quartile range) was 7.9 (7.3-8.7) years. During follow-up, 223 events occurred, of which 122 in men and 101 in women.
The risk of CHD increased with increasing aPWV up to an age-and gender-adjusted hazard ratio of 1.94 (95% confidence interval 1.32-2.85, P ¼ 0.001) for subjects in the highest aPWV tertile compared with subjects in the lowest tertile (P for trend ¼ 0.001) (Table 2, Figure 2) . We divided the subjects into three risk categories (low, intermediate and high 10-year risk of CHD) based on the Framingham covariates. We found a modest model performance (adjusted R 2 5.8%, bootstrap corrected c-index 0.690). Addition of aPWV measurement to the Framingham covariates did not improved the model performance (adjusted R 2 5.6%, bootstrap corrected c-index 0.685) ( Table 3 ). In the low-and high-risk groups, aPWV measurements hardly led to reclassification of subjects into a higher-or lower-risk category. In the low-risk group, 5% (81) of the subjects could be reclassified and in the highrisk group, 6% (20) of the subjects could be reclassified to the intermediate risk group when adding aPWV measurement. In the intermediate-risk group additional measurement of aPWV resulted in slight reclassification. In this category, 3% (29) of the subjects could be reclassified to the high-risk group and 6% (50) of the subjects could be 
Years of follow up
Coronary heart disease free survival Figure 2 Coronary heart disease-free survival by tertiles of aPWV in models adjusted for age and gender. reclassified to the low-risk group (Table 4) . Generally, the observed 10-year risks agreed with the corresponding categories of predicted risk, indicating adequate calibration of the model. In other words, using the model, we were able to predict correctly absolute 10-year risk of CHD (Table 4) . However, the observed 10-year risks in the intermediate risk groups to the low-and high-risk groups agreed less. This suggests that the reclassification in these groups is not totally correct and might not predict the correct 10-year risks. Addition of PWV to the Framingham model did not improve risk classification as indicated by a net reclassification improvement of 0.02% (P ¼ 0.5478). In analysis stratified for gender, we found no differences between men and women (data not shown).
Discussion
In this study performed in a large population of elderly subjects, we found that measurements of aortic stiffness in addition to traditional cardiovascular risk factors led to minor reclassification of subjects within 10-year cardiovascular disease risk categories. Aortic stiffness has been associated with cardiovascular morbidity and mortality in hypertensive subjects, 20 patients with end-stage renal disease, 21 patients with diabetes mellitus 22 and in the general population. 3, 4, 23, 24 Consequently, aortic stiffness has been proposed as an addition to the traditional risk factors for the prediction of cardiovascular disease. Previous findings of the Rotterdam Study 3 reported a slight increase of the c-index when aortic stiffness was added to prediction models containing conventional cardiovascular risk factors. Also in hypertensive subjects, an increase in the area under the curve (AUC) for cardiovascular disease was shown when aPWV was added to the Framingham Risk Score. 20 The recent guidelines for diagnosis and treatment of hypertension 6 have suggested that an aPWV higher than 12m s À1 might be considered as a marker of target organ damage, and a very recent multicentric study has suggested normal and reference values for PWV in large European populations. 25 However, it is still not completely clear whether adding aortic stiffness measurement to the daily practice is of clinical value for the individual patient. Therefore, we investigated the possible clinical predictive value of aortic stiffness, beyond traditional risk factors through reclassification of subjects within the Framingham risk categories, determining the percentages of subjects moving into a higher-or lower-risk category.
We confirmed the association between aortic stiffness and the risk of cardiovascular disease in a population of elderly. However, we found a minor reclassification when adding aortic stiffness to the Framingham risk covariates, suggesting low additional value of aortic stiffness in the clinical management of CHD in the elderly. The minor reclassification showed in this study could have several explanations. First, the prognostic value of several predictors of cardiovascular disease, as aortic stiffness, might decrease with age, because of selective survival and the influence of comorbidity on risk-factor levels. Therefore, we cannot exclude that aortic stiffness could be used for the clinical management of CVD in younger subjects. This has been suggested in a recent study performed within the framework of the Framingham Heart Study, 26 which showed that the addition of aortic stiffness to standard CVD risk factors improved model fit and resulted in a well-calibrated model with improved risk discrimination and risk classification in middle-aged subjects. Second, it has been suggested that the association between a single risk factor and the outcome must be much higher than we traditionally find in observational studies to be useful in predicting absolute risk for individual patients. 27 Therefore, the measurement of aortic stiffness alone might not be adequate to improve cardiovascular risk prediction above traditional factors, but could still be adequate in combination with other additional risk factors and/or noninvasive tests. In accordance with this, the Atherosclerosis Risk in Communities Study 28 added multiple nontraditional risk factors and markers of subclinical disease to traditional risk factors. No single risk marker alone could be identified that improved risk prediction, whereas addition of a set of markers was 3 however, the association of aortic stiffness with cardiovascular disease was somewhat smaller in this study as compared with the previous report, possibly because of a longer follow-up.
Moreover, some methodological limitations need to be considered. First, we choose to refit a model based on Framingham risk factors to stratify our population in the well-known risk categories, because previous research within the Rotterdam study showed that application of the original Framingham Risk Score led to systematic overestimation of CHD risk in men. 29 Second, we restricted the predictors in the model to components of this Framingham Risk Score and included, age, gender, systolic blood pressure, use of antihypertensive medication, total cholesterol, high-density cholesterol, diabetes mellitus and current smoking (yes/no). For this reason, we did not include other risk factors for CHD, including kidney function, body mass index, diastolic blood pressure or measures of atherosclerosis as the carotid intima media thickness. Third, information on measures of stiffness was not available for all subjects who visited the research center. It might be that information was missing mostly in those subjects with a higher cardiovascular risk load. Fourth, the measurements of aortic stiffness were performed only once; it might be speculated that the use of multiple measurements of aortic stiffness could improve accuracy and precision. Finally, these results are obtained in a Caucasian population and therefore the results cannot be extrapolated to other populations.
In this study, we found a limited additional prognostic role of aortic stiffness beyond the traditional cardiovascular risk factors in a population of elderly subjects. Therefore, aortic stiffness no additional value in cardiovascular risk stratification. Considering the increasing interest for functional arterial measurements, further studies in larger cohorts, including also younger subjects are needed to determine the role of aortic stiffness in cardiovascular disease prediction.
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